+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)

  • ID: 4858621
  • Report
  • October 2019
  • Region: Global
  • 423 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Biomay
  • Eurofins Scientific
  • IQVIA Stem Cell Center
  • Pfizer
  • T. Rowe Price Associates
  • MORE

Overview

Over the last 12 months, the pharmaceutical industry reported a year-on-year increment of nearly 75% in funding to support the development of various cell and gene therapies. In fact, close to USD 5 billion has been invested into research on gene-based therapies in the previous two decades. Interestingly, over 2,600 clinical studies have been initiated in this field of research, since 1989. The aforementioned numbers are indicative of the rapid pace of development in this upcoming segment of the biopharmaceutical industry.

The development of such therapy products requires gene delivery vehicles, called vectors, to desired locations within the body (in vivo) / specific cells (ex vivo). The growing demand for such therapies and the rising number of clinical research initiatives in this domain has led to an increase in demand for preclinical and clinical-grade gene delivery vectors. Fundamentally, genetic modifications can be carried out using either viral (such as adenovirus, adeno associated virus (AAV), lentivirus, retrovirus, Sendai virus, herpes simplex virus, vaccinia virus, baculovirus and alphavirus) or non-viral (such as plasmid DNA) vectors. Moreover, recent advances in vector research have led to the development of several innovative viral / non-viral gene delivery approaches.

At present, 10+ genetically modified therapies have received approval / conditional approval in various regions of the world; these include (in the reverse chronological order of year of approval) Zynteglo™ (2019), Zolgensma® (2019), Collategene® (2019), LUXTURNA™ (2017), YESCARTA™ (2017), Kymriah™ (2017), INVOSSA™ (2017), Zalmoxis® (2016), Strimvelis™ (2016), Imlygic® (2015), Neovasculagen® (2011), Rexin-G® (2007), Oncorine® (2005) and Gendicine® (2003). In addition, over 500 therapy candidates are being investigated across different stages of development. The growing number of gene-based therapies, coupled to their rapid progression through the drug development process, has created significant opportunities for companies with expertise in vector manufacturing. Presently, a number of industry (including both well-established companies and smaller R&D-focused initiatives), and non-industry players (academic institutes) claim to be capable of manufacturing different types of viral and non-viral vectors. In addition, there are several players offering novel technology solutions, which are capable of improving existing genetically modified therapy products and upgrading their affiliated manufacturing processes. Considering prevalent and anticipated future trends, we believe that the vector and gene therapy manufacturing market is poised to grow steadily, driven by a robust pipeline of therapy candidates and technical advances aimed at mitigating existing challenges related to gene delivery vector and advanced therapy medicinal products.

Scope of the Report

The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)” report features an extensive study of the rapidly growing market of viral and non-viral vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies with in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • An overview of the current status of the market with respect to the players involved (both industry and non-industry) in manufacturing viral vectors, non-viral vectors and other novel types of vectors. It features information on the year of establishment, scale of production, type of vectors manufactured, location of manufacturing facilities, applications of vectors (in gene therapy, cell therapy, vaccines and others), and purpose of production (fulfilling in-house requirements / for contract services).
  • An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency, and dose strength.
  • An estimate of the overall, installed vector manufacturing capacity of industry players based on information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by vector type (viral vector and plasmid DNA), scale of operation (clinical and commercial), size of the company / organization (small-sized, mid-sized and large) and key geographical regions (North America, Europe, Asia Pacific and the rest of the world).
  • An in-depth analysis of viral vector and plasmid DNA manufacturers, featuring three schematic representations; namely [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type (industry and non-industry) and the size of the industry player (small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of vector manufacturing hubs.
  • An analysis of recent collaborations  and partnership agreements inked in this domain since 2015; it includes details of deals that were/are focused on the manufacturing of vectors, which were analyzed on the basis of year of agreement, type of agreement, type of vector involved, and scale of operation (laboratory, clinical and commercial).
  • An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models/approaches that may be adopted by product developers/manufacturers in order to decide the prices of proprietary vectors.
  • An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on scale of operation). Each profile features an overview of the company/organization, its financial performance (if available), information on its manufacturing facilities, vector manufacturing technology and an informed future outlook.
  • A discussion on the factors driving the market and the various challenges associated with the vector production process.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different vector types, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of  [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 160 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. Our opinions and insights presented in this study were influenced by discussions held with several key players in this domain. The report features detailed transcripts of interviews held with the stakeholders:

  • Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  • Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
  • Joost van den Berg (Director, Amsterdam BioTherapeutics Unit)
  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  • Colin Lee Novick (Managing Director, CJ Partners)
  • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
  • Semyon Rubinchik (Scientific Director, ACGT)
  • Alain Lamproye (President of Biopharma Business Unit, Novasep)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vehicles. The chapter also provides a brief description of the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest trends and innovations in the contemporary vector manufacturing market.

Chapter 4 provides a detailed overview of around 80 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, scale of production, type of viral vectors manufactured (AAV, adenoviral, lentiviral, retroviral and others), location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of production (fulfilling in-house requirements / for contract services).

Chapter 5 provides an overview of around 30 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 6 provides an overview of around 80 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene therapies. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, type of vectors manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others), applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).

Chapter 7 features detailed profiles of the US-based contract service providers / in-house manufacturers that possess commercial-scale capacities for the production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.

Chapter 8 features detailed profiles of EU based contract service providers / in-house manufacturers that possess commercial-scale capacities for the production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 9 features detailed profiles of Asia-Pacific based contract service provider(s) / in-house manufacturer(s) that possess commercial scale capacities for production of viral vectors/plasmid DNA. Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.

Chapter 10 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus-based vectors, Sendai virus-based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development/manufacturing of some of these novel vectors.

Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships related to the manufacturing of vectors or gene therapies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers/acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2015. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale of production and purpose of manufacturing (fulfilling in-house requirement/contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid DNA manufacturers based on the type of organization (industry / non-industry) and size of employee base. The chapter also consists of six world map representations of manufacturers of viral / non-viral vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a schematic world map representation to highlight the locations of global vector manufacturing hubs across different continents.

Chapter 13 highlights our views on the various factors that may be taken into consideration while pricing viral vectors/plasmid DNA. It features discussions on different pricing models/approaches that manufacturers may choose to adopt to decide the prices of their proprietary products.

Chapter 14 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analysed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 15 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the vector production capabilities of the organizations across different types of vectors (viral vectors, plasmid DNA, and both), scale of operation (clinical and commercial) and geographies (North America, EU, Asia-Pacific and the rest of the world).

Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world). Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 17 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process. This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.

Chapter 18 presents insights from the survey conducted on over 160 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 20 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder / President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells),  Laurent Ciavatti (Business Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics),  Semyon Rubinchik (Scientific Director, ACGT), Alain Lamproye (President of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), and Nicolas Grandchamp (R&D Leader, GEG Tech).

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • Biomay
  • Eurofins Scientific
  • IQVIA Stem Cell Center
  • Pfizer
  • T. Rowe Price Associates
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Methods of Gene Transfer
3.3. Viral Vectors for Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
 
3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors
3.5.5. Gene Delivery using Non-Viral Vectors
3.5.5.1. Biolistic Methods
3.5.5.2. Electroporation
3.5.5.3. Receptor Mediated Gene Delivery
3.5.5.4. Gene Activated Matrix (GAM)
 
3.6. Applications of Viral and Non-Viral Vectors
3.6.1. Type of Therapy
3.6.1.1. Gene Therapy
3.6.1.2. Vaccinology
 
3.7. Current Trends in Vector Development / Manufacturing
3.7.1. Vector Engineering
3.7.2. Cargo Engineering
 
3.8. Vector Manufacturing
3.8.1. Types of Vector Manufacturers
3.8.2. Viral Vector Manufacturing Processes
3.8.2.1 Vector Production
3.8.2.2. Adherent and Suspension Cultures
3.8.2.3. Unit Process Versus Multiple Parallel Processes
3.8.2.4. Cell Culture Systems for Production of Viral Vectors
3.8.2.4.1. Small / Laboratory Scale Cell Culture Systems
3.8.2.4.2. Large Scale Cell Culture Systems
3.8.2.4.2.1. Stirred-Tank Reactor Systems
3.8.2.4.2.2. Fixed Bed Reactor / Packed Bed Reactor
3.8.2.4.2.3. WAVE Bioreactor System
3.8.2.5. Serum-Containing versus Serum-Free Media
 
3.8.3. Bioprocessing of Viral Vectors
3.8.3.1. AAV Vector Production
3.8.3.2. Adenoviral Vector Production
3.8.3.3. Lentiviral Vector Production
3.8.3.4. γ -Retroviral Vector Production
3.8.4. Challenges Related to Vector Manufacturing
 
3.9. Future of Vector Manufacturing
 
4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location of Headquarters
4.2.4. Analysis by Geographical Location of Manufacturing Facilities
4.2.5. Analysis by Type of Manufacturer
4.2.6. Analysis by Purpose of Production
4.2.7. Analysis by Type of Vector
4.2.8. Analysis by Scale of Production
4.2.9. Analysis by Application Area
 
5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geographical Location of Headquarters
5.2.4. Analysis by Geographical Location of Manufacturing Facilities
5.2.5. Analysis by Type of Manufacturer
5.2.6. Analysis by Purpose of Production
5.2.7. Analysis by Scale of Production
5.2.8. Analysis by Application Area
 
6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Geographical Location of Manufacturing Facilities
6.2.3. Analysis by Purpose of Production
6.2.4. Analysis by Scale of Production
6.2.5. Distribution by Application Area
 
7. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Aldevron
7.2.1. Company Overview
7.2.2. Manufacturing Facilities
7.2.3. Manufacturing Experience
7.2.4. Future Outlook
 
7.3. BioReliance / SAFC Commercial (Merck KGaA)
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Vector Manufacturing Technology Portfolio
7.3.4. Manufacturing Facilities
7.3.5. Future Outlook
 
7.4. bluebird bio
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Manufacturing Facilities
7.4.4. Manufacturing Experience
7.4.5. Future Outlook
 
7.5. Brammer Bio
7.5.1. Company Overview
7.5.2. Manufacturing Facilities
7.5.3. Manufacturing Experience
7.5.4. Future Outlook
 
7.6. FUJIFILM Diosynth Biotechnologies
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Manufacturing Facilities
7.6.4. Manufacturing Experience
7.6.5. Future Outlook
 
7.7. MassBiologics
7.7.1. Company Overview
7.7.2. Manufacturing Facilities
7.7.3. Future Outlook
 
7.8. Novasep
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Manufacturing Facilities
7.8.4. Manufacturing Experience
7.8.5. Future Outlook
 
7.9. Spark Therapeutics
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. Manufacturing Facilities
7.9.4. Vector Manufacturing Technology Portfolio
7.9.5. Manufacturing Experience
7.9.6. Future Outlook
 
7.10. Vigene Biosciences
7.10.1. Company Overview
7.10.2. Manufacturing Facilities
7.10.3. Vector Manufacturing Technology Portfolio
7.10.4. Manufacturing Experience
7.10.5. Future Outlook
 
8. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE
8.1. Chapter Overview
8.2. Biovian
8.2.1. Company Overview
8.2.2. Manufacturing Facilities
8.2.3. Future Outlook
 
8.3. Cell and Gene Therapy Catapult
8.3.1. Company Overview
8.3.2. Manufacturing Facilities
8.3.3. Future Outlook
 
8.4. Cobra Biologics
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. Manufacturing Facilities
8.4.4. Vector Manufacturing Technology Portfolio
8.4.5. Manufacturing Experience
8.4.6. Future Outlook
 
8.5. FinVector
8.5.1. Company Overview
8.5.2. Manufacturing Facilities
8.5.3. Viral Vector Manufacturing Technology
8.5.4. Future Outlook
 
8.6. Kaneka Eurogentec
8.6.1. Company Overview
8.6.2. Manufacturing Facilities
8.6.3. Manufacturing Experience
8.6.4. Future Outlook
 
8.7. Lonza
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Vector Manufacturing Technology Portfolio
8.7.4. Manufacturing Facilities
8.7.5. Future Outlook
 
8.8. MolMed
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Manufacturing Facilities
8.8.4. Manufacturing Experience
8.8.5. Future Outlook
 
8.9. Oxford BioMedica
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Manufacturing Facilities
8.9.4. Vector Manufacturing Technology Portfolio
8.9.5. Manufacturing Experience
8.9.6. Future Outlook
 
8.10. Richter-Helm
8.10.1. Company Overview
8.10.2. Manufacturing Facilities
8.10.3. Future Outlook
 
8.11. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
8.11.1. Company Overview
8.11.2. Financial Information
8.11.3. Manufacturing Facilities
8.11.4. Manufacturing Experience
8.11.5. Future Outlook
 
8.12. uniQure
8.12.1. Company Overview
8.12.2. Financial Information
8.12.3. Manufacturing Facilities
8.12.4. Vector Manufacturing Technology Portfolio
8.12.5. Future Outlook
 
8.13. VIVEbiotech
8.13.1. Company Overview
8.13.2. Vector Manufacturing Technology Portfolio
8.13.3. Manufacturing Facilities
8.13.4. Future Outlook
 
9. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
9.1. Chapter Overview
9.2. Wuxi AppTec
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Manufacturing Facilities
9.2.4. Manufacturing Experience
9.2.5. Future Outlook
9.3. Other Key Players
 
10. EMERGING VECTORS
10.1. Chapter Overview
10.1.1. Alphavirus Based Vectors
10.1.2. Anc80 Based Vectors
10.1.3. Bifidobacterium longum Based Vectors
10.1.4. Cytomegalovirus Based Vectors
10.1.5. Listeria monocytogenes Based Vectors
10.1.6. Minicircle DNA Based Vectors
10.1.7. Modified Vaccinia Ankara Based Vectors
10.1.8. Myxoma Virus Based Vectors
10.1.9. Self-Complementary Vectors
10.1.10. Sendai Virus Based Vectors
10.1.11. Sleeping Beauty Transposons
 
11. RECENT COLLABORATIONS AND PARTNERSHIPS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Vector and Gene Therapy Manufacturing: Recent Collaborations and Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Type of Vector
11.3.4. Analysis by Scale of Operation
11.3.5. Most Active Players: Analysis by Number of Partnerships
11.3.6. Regional Analysis
11.3.6.1. Most Active Players in Different Geographical Regions
11.3.6.2. Intercontinental and Intracontinental Agreements
11.4. Other Collaborations
 
12. KEY INSIGHTS
12.1. Chapter Overview
12.2. Vector and Gene Therapy Manufacturers: Analysis of Competitive Landscape by Purpose of Production, Type of Vector and Scale of Operation
12.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector
12.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
12.4.1. Contract Manufacturers
12.4.2. In-House Manufacturers
12.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector
12.5.1. AAV Vector Manufacturers
12.5.2. Adenoviral Vector Manufacturers
12.5.3. Lentiviral Vector Manufacturers
12.5.4. Retroviral Vector Manufacturers
12.5.5. Plasmid DNA Manufacturers
 
13. VIRAL VECTOR AND PLASMID DNA COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA Based Therapies
13.3. Viral Vector and Plasmid DNA Based Therapies: Pricing Models
13.3.1. On the Basis of Expert Opinions
13.3.2. On the Basis of Manufacturing Cost
13.3.2.1. On the Basis of Technology Used
13.3.2.2. On the Basis of Scale of Manufacturing
13.3.2.3. On the Basis of Client Type
13.3.3. Prices of Different Types of Vectors
13.4. Concluding Remarks
 
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Installed, Global Viral Vector Manufacturing Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Location of Manufacturing Facilities
14.3.3. Analysis by Scale of Operation
 
14.4. Installed, Global Plasmid DNA Manufacturing Capacity
14.4.1. Analysis by Company Size
14.4.2. Analysis by Location of Manufacturing Facilities
14.4.3. Analysis by Scale of Operation
 
14.5. Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity
14.6. Concluding Remarks
 
15. DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Assumptions and Methodology
 
15.3. Global, Clinical Demand for Viral Vector and Plasmid DNA
15.3.1. Analysis by Geographical Location
15.3.2. Analysis by Type of Vector
15.3.3. Analysis by Type of Therapy
 
15.4. Global, Commercial Demand for Viral Vector and Plasmid DNA
15.4.1. Analysis by Geographical Location
15.4.2. Analysis by Type of Vector
15.4.3. Analysis by Type of Therapy
 
15.5. Demand and Supply Analysis
15.6. Concluding Remarks
 
16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope of the Forecast
16.3. Input Tables and Key Assumptions
16.4. Forecast Methodology
16.5. Overall Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030
16.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Type of Vector
16.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Market Attractiveness by Type of Vector
16.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area
16.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Therapeutic Area
16.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Operation
16.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Production
16.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography
 
16.6. Current and Future Market Opportunity from Commercial Products
16.6.1. AAV Vectors
16.6.1.1. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.1.2. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.1.3. AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
 
16.6.2. Adenoviral Vectors
16.6.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
 
16.6.3. Lentiviral Vectors
16.6.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
 
16.6.4. Retroviral Vectors
16.6.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
 
16.6.5. Plasmid DNA
16.6.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area
16.6.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Therapeutic Area
16.6.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography
16.6.6. Other Viral and Non-Viral Vectors
 
16.7. Opportunity from Clinical Candidates
16.7.1. AAV Vectors
16.7.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.1.2. AAV Vector Manufacturing Market for Clinical Products, 2019-2030: Distribution by Phase of Development
16.7.1.3. AAV Vector Manufacturing Market for Clinical Products, 2019-2030: Distribution by Geography
 
16.7.2. Adenoviral Vectors
16.7.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
16.7.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
 
16.7.3. Lentiviral Vectors
16.7.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
16.7.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
 
16.7.4. Retroviral Vectors
16.7.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
16.7.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
 
16.7.5. Plasmid DNA
16.7.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area
16.7.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Development
16.7.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography
16.7.6. Other Viral and Non-Viral Vectors
 
16.8. Opportunity from Preclinical Candidates
16.8.1. AAV Vectors
16.8.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
16.8.8.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.1.4. AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
 
16.8.2. Adenoviral Vectors
16.8.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
16.8.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.2.4. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
 
16.8.3. Lentiviral Vectors
16.8.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
16.8.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.3.4. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
 
16.8.4. Retroviral Vectors
16.8.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
16.8.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.4.4. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
 
16.8.5. Plasmid DNA
16.8.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Application Area
16.8.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Therapeutic Area
16.8.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
16.8.5.4. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Geography
16.8.6. Other Viral and Non-Viral Vectors
 
17. KEY DRIVERS AND CHALLENGES
17.1. Chapter Overview
17.2. Viral Vector and Plasmid DNA Manufacturing Market: Drivers and Challenges
17.2.1. AAV Vectors
17.2.2. Adenoviral Vectors
17.2.3. Lentiviral Vectors
17.2.4. Retroviral Vectors
17.2.5. Plasmid DNA
17.3. Concluding Remarks
 
18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Seniority Level of Respondents
18.3. Type of Vector
18.4. Scale of Production
18.5. Vector Stabilization Technology
18.6. In-house / Contract Operations
 
19. CONCLUDING REMARKS
 
20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Batavia Biosciences
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President
 
20.3. CEVEC Pharmaceuticals
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer
 
20.4. Vigene Biosciences
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer
 
20.5. Clean Cells
20.5.1. Company Snapshot
20.5.2. Interview Transcript: Laurent Ciavatti, Business Development Manager, Olivier Boisteau, Co-Founder / President and Xavier Leclerc, Head of Gene Therapy
 
20.6. Amsterdam BioTherapeutics Unit (AmBTU)
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Joost van den Berg, Director
 
20.7. MGH Viral Vector Development Facility, Massachusetts General Hospital
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Bakhos A Tannous, Director
 
20.8. CJ PARTNERS
20.8.1. Company Snapshot
20.8.2. Interview Transcript: Interview Transcript, Colin Lee Novick, Managing Director
 
20.9. Delphi Genetics
20.9.1. Company Snapshot
20.9.2. Interview Transcript: Cedric Szpirer, Executive & Scientific Director
 
20.10. ACGT
20.10.1. Company Snapshot
20.10.2. Interview Transcript: Semyon Rubinchik, Scientific Director
 
20.11. Novasep
20.11.1. Company Snapshot
20.11.2. Interview Transcript: Alain Lamproye, President of Biopharma Business Unit
 
20.12. Richter-Helm
20.12.1. Company Snapshot
20.12.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development
 
20.13. Waisman Biomanufacturing
20.13.1. Company Snapshot
20.13.2. Interview Transcript: Brian M Dattilo, Business Development Manager
 
20.14. Plasmid Factory
20.14.1. Company Snapshot
20.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager
 
20.15. GEG Tech
20.15.1. Company Snapshot
20.15.2. Interview Transcript: Nicolas Grandchamp, R&D Leader
 
21. APPENDIX I: TABULATED DATA
 
22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4D Molecular Therapeutics
  • AbbVie
  • Abeona Therapeutics
  • Acucela
  • Adaptimmune Therapeutics
  • Addgene
  • Aduro Biotech
  • Advanced BioScience Laboratories (ABL)
  • Advanced Biotherapeutics Consulting
  • Advaxis
  • ADVENT
  • Adverum Biotechnologies (previously known as Avalanche Biotechnologies)
  • Agenzia Italiana del Farmaco
  • Agilent Technologies
  • Agilis Biotherapeutics
  • Aldevron
  • Allele Biotechnology
  • Alma Bio Therapeutics
  • AlphaVax
  • Althea Technologies
  • American Gene Technologies
  • Amgen
  • AMSBIO
  • Amsterdam BioTherapeutics Unit (AmBTU)
  • Anaeropharma Science
  • Anemocyte
  • apceth Biopharma
  • Applied Biological Materials (ABM)
  • Applied Genetic Technologies (AGTC)
  • Applied Viromics
  • ARCO Design/Build
  • Areta International
  • Asklepios BioPharmaceutical
  • Atlantic Bio GMP
  • ATVIO Biotech
  • Audentes Therapeutics
  • Autolus
  • AveXis
  • Avista Capital Partners
  • AVROBIO
  • Bamboo Therapeutics
  • Batavia Biosciences
  • Bavarian Nordic
  • Baxter
  • Beckman Research Institute
  • Belfer Gene Therapy Core Facility, Cornell University
  • Belfer Gene Therapy Core Facility, Cornell University
  • Benitec Biopharma
  • BioCancell
  • Biogen
  • Biomay
  • Biomiga
  • BioNTech Innovative Manufacturing Service (previously known as Eufects)
  • BioReliance
  • Biotec Services International
  • Biotechnology Department of San Raffaele
  • Biotherapeutics Development Unit, Cancer Research UK
  • Biotie Therapies
  • Bioverativ
  • BioVex
  • Biovian
  • Blue Sky BioServices
  • Bluebird Bio (previously known as Genetix Pharmaceuticals)
  • B-MoGen Biotechnologies
  • Boehringer Ingelheim BioXcellence™
  • Brammer Bio (now a part of Thermo Fisher Scientific)
  • Brazilian Biosciences National Laboratory (LNBio)
  • BRC Clinical Research Facility and Cell Therapy Unit, King's College London
  • Brewin Dolphin
  • Bristol-Myers Squibb
  • Brookside Capital
  • California Institute for Regenerative Medicine
  • California Institute of Technology
  • Calimmune
  • Cancer Research UK
  • Capsugel
  • Carnegie Institution for Science
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • Celladon
  • Cellectis
  • Cellular Biomedicine Group
  • Celonic
  • Center for Biomedicine & Genetics, City of Hope
  • Center for Cell & Gene Therapy, Baylor College of Medicine
  • Center for Cell and Gene Processing, Takara Bio
  • Centre for Cell and Vector Production, Centre for Commercialization of Regenerative Medicine
  • CEVEC Pharmaceuticals
  • Chiesi Farmaceutici
  • Children's GMP, St. Jude Children's Research Hospital
  • Children's Hospital of Philadelphia
  • CIEMAT
  • Cincinnati Children's Hospital Medical Center
  • Clean Cells
  • Clinical Biotechnology Centre, NHS Blood and Transplant
  • Clinical Vector Production Core, University of Pittsburgh
  • Cobra Biologics
  • CombiGene
  • Core Facility for Therapeutic Vectors, Institute of Medical Science Research Hospital
  • Cranfield University
  • Creative Biogene
  • Creative Biolabs
  • Creed Commercial Development
  • Cytovance Biologics
  • Deerfield Management
  • Delphi Genetics
  • Department of Neuroscience, University of Minnesota
  • Desktop Genetics
  • Division of Human Gene Therapy, Stanford University
  • DNAtrix
  • Elixirgen Scientific
  • Emergent BioSolutions
  • Epeius Biotechnologies
  • EUFETS
  • Eurofins Genomics
  • Eurofins Scientific
  • European Society of Gene and Cell Therapy
  • ExcellGene
  • Finnish Bioindustries
  • FinVector (previously known as Ark Therapeutics)
  • Fisher BioServices
  • Five Prime Therapeutics
  • FKD Therapies
  • Flash Therapeutics
  • Florida Biologix
  • Fondazione Telethon
  • Foundation Fighting Blindness
  • Fraunhofer Institute for Toxicology and Experimental Medicine
  • Freeline Therapeutics
  • FUJIFILM Diosynth Biotechnologies
  • GE Healthcare
  • GEG Tech
  • Genable Technologies
  • Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • Gene Editing and Viral Vector Core, City of Hope
  • Gene Editing and Viral Vector Core, City of Hope
  • Gene Medicine Japan
  • Gene Silencing and Expression Facility, Robinson Research Institute, University of      Adelaide
  • Gene Therapy Clinical Vector Production Core, University of Pittsburgh
  • Gene Therapy Research Institute
  • Gene Transfer Vector Core, Grousbeck Gene Therapy Center
  • Gene Transfer Vector Core, Schepens Eye Research Institute
  • Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
  • GeneCure Biotechnologies
  • GeneDetect
  • GeneImmune Biotechnology
  • Genethon
  • GENEWIZ
  • GenIbet Biopharmaceuticals
  • GenScript
  • GenVec
  • Genzyme
  • GIGA Institute, Liege Universite
  • Gilead Sciences
  • GlaxoSmithKline
  • Green Cross LabCell
  • Guy's Hospital, London
  • Hercules Capital
  • Hong Kong Institute of Biotechnology
  • Hookipa Biotech
  • Hope Center Viral Vectors Core, Washington University School of Medicine
  • Horizon Discovery
  • Hospital de Sant Pau
  • Human Gene and Cell Therapy Center, Akdeniz University
  • Human Stem Cells Institute
  • ID Pharma (previously known as DNAVEC)
  • Immune Design
  • Immune Technology
  • ImmunoGenes
  • Immunomic Therapeutics
  • Inbiomed
  • Indiana University Vector Production Facility
  • Instituto de Tecnologia Química e Biológica António Xavier
  • Intrexon
  • InvivoGen
  • IPPOX Foundation
  • IQVIA Stem Cell Center
  • Janelia Research Campus
  • Janssen
  • Kalon Biotherapeutics
  • Kaneka Eurogentec
  • Kelley School of Business, Indiana University
  • King's College London, Guy's and St Thomas' NHS Foundation Trust
  • Kite Pharma
  • Kobe Biomedical Innovation Cluster
  • Kolon Life Sciences
  • Laboratory of Malaria Immunology and Vaccinology
  • Lentigen Technology
  • Lentiviral Lab, USC School of Pharmacy
  • Leuven Viral Vector Core
  • Lonza
  • Luminous BioSciences
  • Lund University
  • Lysogene
  • Massachusetts Eye and Ear
  • Massachusetts Life Science Center
  • MassBiologics
  • MaxCyte
  • Medigene
  • MeiraGTx
  • Merck
  • Merck Serono
  • Merial
  • Michael J. Fox Foundation for Parkinson Research
  • Mila's Miracle Foundation
  • MilliporeSigma
  • Ministry of Economy and Competitiveness
  • Mitsubishi
  • Molecular Diagnostic Services
  • Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University
  • MolMed
  • Myeloma Crowd Research Initiative
  • NanoCor Therapeutics
  • Nantes Gene Therapy Institute
  • National Cancer Institute
  • National Center for Advancing Translational Sciences
  • National Human Genome Research Institute
  • National Institute of Neurodegenerative Disorders and Stroke Center Core, University of Minnesota
  • National Institutes of Health
  • National Virus Vector Laboratory, University of Eastern Finland
  • Nature Technology
  • Naval Medical Research Center
  • Neuroscience CenterVector Core, Massachusetts General Hospital
  • Neuroscience Gene Vector and Virus Core, Stanford Medicine
  • NewLink Genetics
  • Nikon CeLL innovation
  • Novartis
  • Novasep
  • Ocular Gene Therapy Core, National Eye Institute
  • Okairos
  • Omnia Biologics
  • Orchard Therapeutics
  • Oxford BioMedica
  • Oxford Genetics
  • PacificGMP
  • Paragon Gene Therapy, Catalent Biologics
  • Penn Vector Core, University of Pennsylvania
  • Pfizer
  • PharmaChem Technologies
  • Pinchal & Company
  • PlasmidFactory
  • Powell Gene Therapy Center, University of Florida
  • Precigen
  • ProBioGen
  • ProMab Biotechnologies
  • Protein Sciences
  • Provecs Medical
  • Puresyn
  • Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia
  • Rayne Cell Therapy Suite, King's College London
  • REGENXBIO
  • Renova Therapeutics
  • Richter-Helm BioLogics
  • RIKEN BioResource Research Center
  • Roche
  • Rock Springs Capital
  • Rocket Pharmaceuticals
  • SAB-Technology
  • SAFC
  • Sanofi CEPiA
  • Sanofi Genzyme
  • Sanofi Pasteur
  • Sartorius Stedim Biotech
  • Scancell
  • Selecta Biosciences
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • SignaGen Laboratories
  • SillaJen
  • Sino Biological
  • SIRION Biotech
  • Sofinnova Ventures
  • Spark Therapeutics
  • St Thomas' NHS Foundation Trust
  • Stevenage Bioscience Catalyst
  • Strathmann Biotec
  • Stratophase
  • Synpromics
  • Synthace
  • Synthetic Genomics
  • System Biosciences
  • T. Rowe Price Associates
  • Tecrea
  • Terry Fox Laboratory
  • Texas A&M University
  • The Finnish Fair Foundation
  • The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Organization
  • The Jarvis Lab
  • The Wellcome Trust
  • The Wellcome Trust / BRC Clinical Research Facility and Cell Therapy Unit (CTU), King’s College London
  • TheraBiologics
  • THERAVECTYS
  • Therexsys
  • Thermo Fisher Scientific
  • TissueGene
  • Touchlight Genetics
  • Transgene
  • Treeway
  • Twist Bioscience
  • TxCell
  • UAB Vector Production Facility
  • uniQure
  • Unit Biotech & ATMP’s, University Medical Center Groningen
  • UniTech Pharma
  • University of Florida
  • University of Iowa Research Foundation
  • University of Liège
  • University of Massachusetts Medical School System
  • University of Oxford Clinical BioManufacturing Facility
  • University of Virginia School of Medicine
  • Vaccibody
  • Vaccine and Gene Therapy Institute
  • Valneva
  • VBI Vaccine
  • Vectalys
  • Vector Biolabs
  • Vector Core / GMP Facility, UC Davis Health
  • Vector Core Laboratory, Powell Gene Therapy Center, University of Florida
  • Vector Core of Gene Therapy, Laboratory of Nantes
  • Vector Core, Harvard Gene Therapy Initiative
  • Vector Core, Telethon Institute of Genetics and Medicine
  • Vector Core, University of Michigan Medical School
  • Vector Core, University of North Carolina
  • Vector Development and Production Facility, Roswell Park Comprehensive Cancer Center
  • Vector Development Core Laboratory, UC San Diego School of Medicine
  • Vector Production Facility, Indiana University
  • Vecura GMP Laboratory, Karolinska Institutet
  • VGXI
  • Vibalogics
  • Vical
  • Vigene Biosciences
  • Viral Core Facility, NeuroCure
  • Viral Core, Seattle Children's Research Institute
  • Viral Gene Transfer Core, Massachusetts Institute of Technology
  • Viral Vector and Cloning Core, University of Minnesota
  • Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital
  • Viral Vector Core Facility, University of Iowa Carver College of Medicine
  • Viral Vector Core Laboratory, National Institute of Environmental Health Sciences
  • Viral Vector Core Laboratory, The University of Tennessee Health Science Center
  • Viral Vector Core, Duke University
  • Viral Vector Core, Emory University School of Medicine
  • Viral Vector Core, Maine Medical Research Institute
  • Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute
  • Viral Vector Core, The Jackson Laboratory
  • Viral Vector Core, The Jenner Institute
  • Viral Vector Core, University of Massachusetts Medical School
  • Viral Vector Core, University of South Carolina School of Medicine
  • Viral Vector Facility, Neuroscience Center Zurich
  • Viral Vector Production Laboratory, Mayo Clinic Cancer Center
  • Viral Vector Production Unit, Universitat Autònoma de Barcelona-Vall d'Hebrón Institut de Recerca
  • Viral Vectors Laboratory, Louisiana State University School of Veterinary Medicine
  • ViralGEN
  • ViroMed
  • Virovek
  • VirusTech Core Facility, Karolinska Institutet
  • Vivante GMP Solutions
  • VIVEbiotech
  • Voyager Therapeutics
  • Waisman Biomanufacturing
  • Weber Laboratory, Icahn School of Medicine at Mount Sinai
  • Wellington Management
  • West Biotherapy (also known as EFS Atlantic Bio GMP)
  • Wolfson Gene Therapy Unit, University College of London
  • WuXi AppTec
  • Xpress Biologics
  • Yposkesi
  • Ziopharm Oncology
Note: Product cover images may vary from those shown
5 of 4

 

 

Loading
LOADING...

Adroll
adroll